BNP Paribas Asset Management
BBIO icon

BNP Paribas Asset Management’s BridgeBio Pharma BBIO Stock Holding History

BNP Paribas Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.53M Sell
87,838
-292
-0.3% -$20.5K 0.01% 823
2026
Q1 		$6.54M Buy
88,130
+86,172
+4,401% +$6.25M 0.01% 792
2025
Q4 		$150K Buy
1,958
+589
+43% +$38.7K ﹤0.01% 1384
2025
Q3 		$71K Buy
1,369
+123
+10% +$6K ﹤0.01% 944
2025
Q2 		$54K Buy
+1,246
New +$45.3K ﹤0.01% 1114

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

BNP Paribas Asset Management's BBIO Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its BridgeBio Pharma (BBIO) stake by 0.33% in Q2 2026, selling an estimated $20.5K and leaving 87,838 shares worth $6.53M. The position accounts for 0.01% of the portfolio, ranked #823.

BNP Paribas Asset Management first reported a position in BBIO in Q2 2025 and has held it in 5 quarters since. The position peaked at $6.54M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • BNP Paribas Asset Management held 87,838 shares of BridgeBio Pharma worth $6.53M as of Q2 2026.
  • BNP Paribas Asset Management sold 292 BridgeBio Pharma shares in Q2 2026, an estimated $20.5K.
  • BridgeBio Pharma made up 0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #823 holding.
  • BNP Paribas Asset Management first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's BridgeBio Pharma position peaked at $6.54M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.